Press release
Chronic Myelomonocytic Leukemia Pipeline 2025: Innovative Clinical Developments by 20+ Global Leaders - DelveInsight | Featuring ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CA
Chronic Myelomonocytic Leukemia Pipeline 2025
As Chronic Myelomonocytic Leukemia (CMML) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective treatments. DelveInsight reports that more than 20 pharmaceutical and biotech companies are actively developing over 25 therapeutic candidates targeting CMML. These candidates span multiple stages of clinical and preclinical development, reflecting significant innovation and commitment to addressing this critical health challenge.
The "Chronic Myelomonocytic Leukemia Pipeline Insight 2025" report by DelveInsight provides a comprehensive strategic overview of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving CMML therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Chronic Myelomonocytic Leukemia Drug Development [https://www.delveinsight.com/report-store/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Key Takeaways from the Chronic Myelomonocytic Leukemia Pipeline Report
DelveInsight's Chronic Myelomonocytic Leukemia (CMML) pipeline report highlights a dynamic landscape, with over 20 active companies developing more than 25 therapeutic candidates for CMML treatment.
Key developments in 2025 include:
*
July 2025: The oral therapy Inqovi (venetoclax for acute myeloid leukemia) is under FDA review, with a decision expected by February 25, 2026.
*
July 2025: Taiho Oncology and Taiho Pharmaceutical announced the FDA's acceptance of a supplemental New Drug Application for INQOVI Registered in combination with venetoclax to treat patients with acute myeloid leukemia.
Leading companies advancing CMML therapies include ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CAR, Cobimetinib, BC3402, AZD6738, APG-115, Tuspetinib, NC525, Itacitinib, LP-108, TRX103, PRT2527, DFV890, and others.
Promising pipeline candidates in various stages of development include Timdarpacept, IO-202, STX-0712, among others.
Chronic Myelomonocytic Leukemia Overview:
Chronic myelomonocytic leukemia (CMML) is a rare blood disorder caused by the abnormal clonal expansion of hematopoietic stem cells. It is characterized by elevated monocyte counts and dysplasia (abnormal development) of myeloid precursor cells in the bone marrow. CMML falls under the category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a group that also includes atypical CML, juvenile myelomonocytic leukemia, MDS/MPN with ring sideroblasts and thrombocytosis, and other unclassified subtypes.
Download the Chronic Myelomonocytic Leukemia sample report to know in detail about the Chronic Myelomonocytic Leukemia treatment market [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Chronic Myelomonocytic Leukemia Pipeline Analysis
The Chronic Myelomonocytic Leukemia pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Chronic Myelomonocytic Leukemia Market.
*
Categorizes Chronic Myelomonocytic Leukemia therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Chronic Myelomonocytic Leukemia drugs under development based on:
*
Stage of development
*
Chronic Myelomonocytic Leukemia Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Chronic Myelomonocytic Leukemia Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Chronic Myelomonocytic Leukemia Licensing agreements
*
Funding and investment activities supporting future Chronic Myelomonocytic Leukemia market advancement.
Unlock key insights into emerging Chronic Myelomonocytic Leukemia therapies and market strategies here: https://www.delveinsight.com/report-store/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Chronic Myelomonocytic Leukemia Emerging Drugs
*
Timdarpacept: ImmuneOnco Biopharma
Timdarpacept is an experimental therapy in Phase III development for chronic myelomonocytic leukemia (CMML). It is a recombinant fusion protein that links Signal Regulatory Protein alpha (SIRP) to an IgG1 backbone, designed to enhance immune system activity against cancer cells.
*
IO-202: Immune-Onc Therapeutics
IO-202 is a novel, humanized IgG1 monoclonal antibody designed to target LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B4), a receptor that is highly expressed on cells linked to chronic myelomonocytic leukemia (CMML). By binding to LILRB4, IO-202 stimulates the immune system to attack cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), promoting the destruction of malignant cells.
Chronic Myelomonocytic Leukemia Pipeline Therapeutic Assessment
Chronic Myelomonocytic Leukemia Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Chronic Myelomonocytic Leukemia By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Chronic Myelomonocytic Leukemia Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Chronic Myelomonocytic Leukemia Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Chronic Myelomonocytic Leukemia therapies and key Chronic Myelomonocytic Leukemia companies [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Chronic Myelomonocytic Leukemia Current Treatment Patterns
4. Chronic Myelomonocytic Leukemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Myelomonocytic Leukemia Late-Stage Products (Phase-III)
7. Chronic Myelomonocytic Leukemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Myelomonocytic Leukemia Discontinued Products
13. Chronic Myelomonocytic Leukemia Product Profiles
14. Chronic Myelomonocytic Leukemia Key Companies
15. Chronic Myelomonocytic Leukemia Key Products
16. Dormant and Discontinued Products
17. Chronic Myelomonocytic Leukemia Unmet Needs
18. Chronic Myelomonocytic Leukemia Future Perspectives
19. Chronic Myelomonocytic Leukemia Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Chronic Myelomonocytic Leukemia pipeline reports offerings [https://www.delveinsight.com/report-store/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-myelomonocytic-leukemia-pipeline-2025-innovative-clinical-developments-by-20-global-leaders-delveinsight-featuring-immuneonco-biopharma-immuneonc-therapeutics-solu-therapeutics-cd4ca]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Myelomonocytic Leukemia Pipeline 2025: Innovative Clinical Developments by 20+ Global Leaders - DelveInsight | Featuring ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CA here
News-ID: 4231495 • Views: …
More Releases from ABNewswire
Wizmo, Inc. Announces Microsoft FoxPro Modernization Services for Mission-Critic …
Eagan, MN - October 20, 2025 - Wizmo, Inc., a private-cloud hosting and legacy application services company, announced Microsoft FoxPro modernization services [https://wizmo.com/microsoft-foxpro-support-migration/] for organizations still running critical processes on FoxPro. These services emphasize continuity for customers-keeping daily billing, inventory, and reporting on track-while adding dependable access for remote staff and stronger protection of data.
With practical timelines and hands-on guidance, Wizmo helps teams modernize legacy platforms without losing the systems…
Personal Injury Lawyer in Arkansas Joseph Gates Discusses Comparative Negligence
Little Rock, Arkansas - Personal injury lawyer in Arkansas, Joseph Gates of Gates Law Firm, PLLC (https://www.gateslawpllc.com/what-is-comparative-negligence-in-arkansas/), is releasing a clear, client-facing explainer on Arkansas's modified comparative negligence rule, including the pivotal 50% bar that can determine whether an injured party recovers compensation. The guidance addresses how fault is allocated after crashes, falls, and other preventable incidents, and why early case strategy matters for families seeking recovery.
Under Arkansas Code 16-64-122,…
Houston Guardianship Lawyer Whitney L. Thompson Outlines Court-Appointed Guardia …
Houston, Texas - The Law Office of Whitney L. Thompson (https://www.wthompsonlaw.com/no-will-no-plan-the-court-process-for-appointing-guardians/) released a comprehensive overview of how Texas courts appoint guardians for minor children when no will names a preferred caregiver. Houston guardianship lawyer Whitney L. Thompson details the statutory hierarchy, the roles of court-appointed advocates, and key documents that give families stronger control over future care decisions. The guidance underscores the importance of planning that reflects family values while…
New Jersey Gun Crime Attorney Adam M. Lustberg Issues Advisory On Large-Capacity …
Hackensack, NJ - New Jersey gun crime attorney Adam M. Lustberg of Lustberg Law Offices, LLC (https://www.lustberglaw.com/blog/are-large-capacity-magazines-and-bump-stocks-illegal-in-nj/) has released a legal advisory addressing New Jersey's restrictions on large-capacity magazines and bump stocks, outlining current statutory definitions, penalties, narrow exemptions, and defense considerations for individuals charged under these provisions. The advisory explains how state law treats detachable magazines capable of holding more than 10 rounds and trigger-modifying devices, and it highlights…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
